Dec 16, 2025 03:57AM
Nov 13, 2025 07:00AM
Oct 8, 2025 12:58PM
Aug 28, 2025 07:02AM
Aug 19, 2025 07:01AM
Aug 8, 2025 12:20PM
Jul 24, 2025 07:01AM Aldeyra gets European orphan designation for retinitis pigmentosa drug
Jul 17, 2025 07:02AM
Jun 26, 2025 08:18AM
Jun 26, 2025 07:00AM
Jun 18, 2025 03:02PM
Jun 17, 2025 07:02AM
May 6, 2025 07:08AM
May 4, 2025 08:18AM ALDX INQUIRY: BFA Law Notifies Aldeyra Therapeutics, Inc. Investors to Contact the Firm About Pending Investigation into the Company
May 2, 2025 03:33PM
May 1, 2025 03:18PM
Apr 30, 2025 07:36AM
Apr 28, 2025 07:11AM
Apr 26, 2025 07:08AM
Apr 24, 2025 07:36AM
Apr 22, 2025 07:17AM ALDX LEGAL UPDATE: Aldeyra Therapeutics, Inc. Investors are Notified that the Company is being Investigated for Securities Violations and to Contact BFA Law
Apr 20, 2025 07:37AM
Apr 18, 2025 03:23PM
Apr 17, 2025 03:11PM
Apr 16, 2025 08:08AM
Apr 14, 2025 08:07AM
Apr 11, 2025 03:18PM
Apr 10, 2025 07:46AM ALDX CLASS REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about the Pending Securities Investigation
Apr 8, 2025 07:08AM
Apr 7, 2025 05:17AM
Apr 6, 2025 11:08AM
Apr 4, 2025 03:33PM
Apr 4, 2025 02:18PM
Apr 4, 2025 09:34AM
Apr 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)
Apr 3, 2025 03:18PM
Apr 3, 2025 08:01AM
Apr 3, 2025 07:56AM
Mar 17, 2025 05:18AM
Feb 5, 2025 08:24AM
Dec 16, 2024 06:47AM
Nov 18, 2024 10:22AM BTIG Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)
Nov 18, 2024 07:04AM
Oct 3, 2024 02:14PM
Oct 3, 2024 09:30AM
Oct 3, 2024 07:00AM
Oct 1, 2024 06:26AM
Aug 8, 2024 12:42PM
Aug 8, 2024 07:00AM Aldeyra Therapeutics (ALDX) Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
Aug 8, 2024 06:57AM

341,965 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All